MNG72
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.403
- INTERFERON_GAMMA_RESPONSE+0.370
- INTERFERON_ALPHA_RESPONSE+0.368
- IL6_JAK_STAT3_SIGNALING+0.287
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.244
- INFLAMMATORY_RESPONSE+0.215
- PANCREAS_BETA_CELLS+0.165
- COMPLEMENT+0.148
- TNFA_SIGNALING_VIA_NFKB+0.124
- KRAS_SIGNALING_UP+0.119
Top 10 suppressed
- MYC_TARGETS_V2-0.345
- CHOLESTEROL_HOMEOSTASIS-0.323
- PROTEIN_SECRETION-0.323
- ESTROGEN_RESPONSE_EARLY-0.303
- MITOTIC_SPINDLE-0.301
- MTORC1_SIGNALING-0.290
- ANDROGEN_RESPONSE-0.269
- E2F_TARGETS-0.238
- G2M_CHECKPOINT-0.221
- UNFOLDED_PROTEIN_RESPONSE-0.219
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.842 |
| 2 | 46a6f49d-2ab8-41fb-ba8c-951a160e5d08 | — | — | 0.824 |
| 3 | f426318a-9c1a-4476-a087-2b3a84096f5c | — | — | 0.817 |
| 4 | TCGA-C8-A138-01A-11R-A115-07 | — | A | 0.813 |
| 5 | TCGA-GM-A2DA-01A-11R-A18M-07 | — | A | 0.807 |
| 6 | SRR8518332 | — | D | 0.805 |
| 7 | TCGA-90-A59Q-01A-11R-A26W-07 | — | cohortA1 | 0.804 |
| 8 | SRR8943004 | — | — | 0.803 |
| 9 | TCGA-50-5055-01A-01R-1628-07 | — | cohortA1 | 0.803 |
| 10 | SRR5088828 | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.403 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.368 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.287 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.244 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.215 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.165 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.148 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.124 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.119 | Inavolisib | — uncovered |
| COAGULATION | 0.113 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.065 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.064 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.061 | Inavolisib | — uncovered |
| APOPTOSIS | 0.051 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.051 | Idelalisib | — uncovered |
| MYOGENESIS | 0.028 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.005 | Inavolisib | — uncovered |